Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients

Respiratory Medicine

Volumn 100, Issue 8, 2006, Pages 1342-1348

  van de Garde, Ewoudt M W ^a,b   Souverein, Patrick C ^a   van den Bosch, Jules M M ^b   Deneer, Vera H M ^b   Goettsch, Wim G ^c   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

Antibacterial agents; Heart failure; Mortality; Pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; CARDIAC GLYCOSIDE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DIURETIC AGENT; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; NORFLOXACIN; OFLOXACIN; ROXITHROMYCIN; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BRONCHOPNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFLUENZA; LENGTH OF STAY; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NETHERLANDS; PNEUMONIA; RESPIRATORY TRACT DISEASES; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE;

EID: 33745394038     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.11.024     Document Type: Article

References (28)

1. Mortensen E.M., Coley C.M., Singer D.E., et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 162 9 (2002) 1059-1064
2. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275 2 (1996) 134-141
3. Segreti J., House H.R., and Siegel R.E. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 118 Suppl. 7A (2005) 21S-28S
4. Woodhead M.A., Macfarlane J.T., McCracken J.S., Rose D.H., and Finch R.G. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1 8534 (1987) 671-674
5. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56 Suppl 4 (IV) (2001) 1-64
6. Bartlett J.G., Dowell S.F., Mandell L.A., File Jr. T.M., Musher D.M., and Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31 2 (2000) 347-382
7. Boersma W.G. Assessment of severity of community-acquired pneumonia. Semin Respir Infect 14 2 (1999) 103-114
8. McKean M.C. Evidence based medicine: review of BTS guidelines for the management of community acquired pneumonia in adults. J Infect 45 4 (2002) 213-218
9. Niederman M.S., Bass Jr. J.B., Campbell G.D., et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 148 5 (1993) 1418-1426
10. Roson B., Carratala J., Fernandez-Sabe N., Tubau F., Manresa F., and Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 164 5 (2004) 502-508
11. Herings R.M., Bakker A., Stricker B.H., and Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 46 2 (1992) 136-140
12. van Kasteren M.E., Wijnands W.J., Stobberingh E.E., Janknegt R., and van der Meer J.W. Optimization of the antibiotics policy in the Netherlands. II. SWAB guidelines for the antimicrobial therapy of pneumonia in patients at home and as nosocomial infections. The Netherlands Antibiotic Policy Foundation. Ned Tijdschr Geneeskd 142 17 (1998) 952-956
13. Aleva R, Boersma W, Cox A, et al. Guideline diagnosis and treatment of community-acquired pneumonia. Dutch Thoracic Society; 2001 [in Dutch].
14. NHG. The Dutch College of General Practitioners (NHG) practice guideline: acute cough; 2003 [in Dutch].
15. Marrie T.J., and Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 127 4 (2005) 1260-1270
16. Lim W.S., and Macfarlane J.T. Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged>or=75 yrs. Eur Respir J 17 2 (2001) 200-205
17. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 2 (1992) 197-203
18. Johnson D., Carriere K.C., Jin Y., and Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J Clin Pharm Ther 29 3 (2004) 231-239
19. Hak E., Bont J., Hoes A.W., and Verheij T.J. Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract (2005)
20. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 4 (1997) 243-250
21. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58 5 (2003) 377-382
22. Guevara R.E., Butler J.C., Marston B.J., Plouffe J.F., File Jr. T.M., and Breiman R.F. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol 149 3 (1999) 282-289
23. Ruiz M., Ewig S., Marcos M.A., et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 160 2 (1999) 397-405
24. Braun J.J., de Graaff C.S., de Goey J., Zwinderman A.H., and Petit P.L. Community-acquired pneumonia: pathogens and course in patients admitted to a general hospital. Ned Tijdschr Geneeskd 148 17 (2004) 836-840
25. Carroll K.C. Laboratory diagnosis of lower respiratory tract infections: controversy and conundrums. J Clin Microbiol 40 9 (2002) 3115-3120
26. Somberg J.C., and Molnar J. The pharmacologic treatment of heart failure. Am J Ther 11 6 (2004) 480-488
27. Metra M., Nodari S., and Dei Cas L. Current guidelines in the pharmacological management of chronic heart failure. J Renin Angio Aldo Syst 5 Suppl. 1 (2004) S11-S16
28. McKenzie D.B., and Cowley A.J. Drug therapy in chronic heart failure. Postgrad Med J 79 937 (2003) 634-642